A new GSK campaign (print ad above) aims to raise shingles awareness with Spanish-speaking audiences.

February 25, 2022 11:56 AM EST

GlaxoSmithKline amplifies the agony of ‘la culebrilla’ to raise shingles awareness with Spanish speakers

Beth Snyder Bulik

Senior Editor

The burning pain and electric shock-like symptoms of shingles are the same no matter what language you speak. GlaxoSmithKline, however, wants to make sure Spanish-speakers are aware of shingles, or la culebrilla, and that it can be prevented.

Its latest ad campaign features a Spanish-language voiceover in a TV ad showing the pain of shingles, illustrated by corkscrews twisting through skin, smoldering orange burning patches and electrical shocks. The message? Si tuviste varicella (if you’ve had chicken pox) and tiene 50 años o mas (are 50 years or older), you should speak to your doctor about la culebrilla.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

GlaxoSmithKline amplifies the agony of ‘la culebrilla’ to raise shingles awareness with Spanish speakers

Beth Snyder Bulik

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

Glax­o­SmithK­line am­pli­fies the agony of ‘la cule­bril­la’ to raise shin­gles aware­ness with Span­ish speak­ers

Beth Snyder Bulik

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Roche's Genen­tech touts la­bel ex­pan­sion for block­buster lung can­cer drug Ale­cen­sa

GlaxoSmithKline amplifies the agony of ‘la culebrilla’ to raise shingles awareness with Spanish speakers

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa